- BIO CEO & Investor Conference on February 13 -
- RBC Capital Markets Healthcare Conference on February 21 -

NEW YORK, Feb. 06, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group Inc., (Nasdaq:SLS) (SELLAS), a development-stage biopharmaceutical company focused on novel cancer immunotherapies for a broad range of cancer indications, today announced that Angelos Stergiou, M.D., ScD h.c., President and Chief Executive Officer of SELLAS, will present a corporate overview at the following upcoming conferences.

• BIO CEO & Investor Conference 2018
  Date: Tuesday, February 13, 2018
  Presentation Time: 2:30 PM ET
  Location: New York Marriott Marquis, New York, NY

• 2018 RBC Capital Markets Healthcare Conference
  Date: Wednesday, February 21, 2018
  Presentation Time: 2:35 PM ET
  Location: Lotte New York Palace Hotel, New York, NY

A live webcast of each presentation can be accessed on the investor page of SELLAS’ website at www.sellaslifesciences.com/investors.  A replay of each webcast will also be archived for up to 30 days on SELLAS’ website following the conference.  

About SELLAS Life Sciences Group

SELLAS Life Sciences Group is a development-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. SELLAS' lead product candidate, galinpepimut-S (GPS), is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center that targets the Wilms Tumor 1 (WT1) protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination to address a broad spectrum of hematologic cancers and solid tumor indications. GPS is Phase 3-ready for two indications, acute myeloid leukemia (AML) and malignant pleural mesotheliomia (MPM), and is also in development as a potential treatment for multiple myeloma and ovarian cancer. SELLAS plans to study GPS in up to four additional indications. SELLAS recently received Orphan Drug designations from the U.S. Food & Drug Administration (FDA), as well as the European Medicines Agency, for GPS in AML and MPM; GPS also received Fast Track designation for AML and MPM from the FDA.

For more information on SELLAS, please visit www.sellaslifesciences.com.

Investor Contact:
Will O’Connor
Stern Investor Relations, Inc.
212-362-1200
ir@sellaslife.com

David Moser, JD
Sellas Life Sciences Group
813-864-2571
info@sellaslife.com

Source: SELLAS Life Sciences Group, Inc.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.